株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

製薬会社向けADMET (薬物動態毒性) 検査市場:2017年〜2027年

Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies

発行 Visiongain Ltd 商品コード 341090
出版日 ページ情報 英文 149 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=145.77円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
製薬会社向けADMET (薬物動態毒性) 検査市場:2017年〜2027年 Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies
出版日: 2017年06月28日 ページ情報: 英文 149 Pages
概要

製薬会社向けADMET (薬物動態毒性:吸収、分布、代謝、排泄、毒性) 検査市場は、2016年に74億3000万米ドルに達しました。市場は、2022年までのCAGR (複合年間成長率) で、12.32%の成長が予測されています。

当レポートでは、製薬会社向けADMET (薬物動態毒性) 検査市場について調査分析し、市場予測、地域別・国別市場の分析、SWOT・STEP分析、主要企業について、体系的な情報を提供しています。

第1章 レポート概要

第2章 ADMET検査とは

  • ADMET検査とは
  • 生物学的類似性におけるADMET検査の役割
  • 試験設計と実行

第3章 ADMET検査:世界市場

  • 製薬会社向けADMET支出:フェーズ別
  • ADMET検査市場

第4章 ADMET検査:セグメント別の収益

  • 最も収益の大きい部門
  • 予測ADMET検査の需要が急増 (今後10年間)
  • 体外ADMET検査市場
  • 体内ADMET検査市場
  • コンピューターによるADMET検査

第5章 ADMET検査:主な先進市場

  • 主要国市場
  • 主要国市場の予測
  • 北米
  • EU5ヶ国
  • 日本

第6章 ADMET検査:主な新興市場

  • 主な新興市場
  • 成長予測
  • アジア太平洋地域
  • ロシア
  • ブラジル

第7章 ADMET検査産業における主要企業

  • Agilent Technologies, Inc.
  • Dassault Systemes
  • Cyprotex
  • Bio-Rad Laboratories, Inc.
  • Quintiles
  • アジア地域
  • Charles River Laboratories
  • WuXi PharmaTech
  • Promega Corporation

第8章 ADMET検査市場:産業動向

  • SWOT分析
  • STEP分析
  • 技術の向上
  • 経済上の懸念事項
  • 政治・規制の発展

第9章 結論

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0206

The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 149-page report you will receive 100 charts- all unavailable elsewhere.

The 149-page report provides clear detailed insight into the pharma ADMET testing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Pharma ADMET Testing market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the main submarkets:
    • In Vivo ADMET Testing
    • In Vitro ADMET Testing
    • In Silico ADMET Testing

image1

  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • The US
    • Japan
    • Germany
    • France
    • Italy
    • Spain
    • The UK
    • China
    • Brazil
    • Russia
    • India
    • South Korea
    • Rest of the World

Our study includes SWOT and STEP analysis of this industry and market.

  • Our study discusses the selected leading companies that are the major players in the ADMET Testing industry:
    • Agilent Technologies
    • BIOVIA
    • Cyprotex
    • Bio-Rad Laboratories
    • Quintiles
    • CMIC
    • Charles River Laboratories
    • WuXi PharmaTech
    • Promega Corporation
    • Sigma-Aldrich (part of Merck KGaA)

A company profile gives you the following information where available:

  • Recent historical revenues
  • Discussion of a company's activities, technologies and outlook
  • Brief assessment of the company's ADMET strategy

Visiongain's study is intended for anyone requiring commercial analyses for the pharma ADMET Testing market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for ADMET Testing
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. An Introduction to ADMET Testing

  • 2.1 What Is ADMET Testing?
    • 2.1.1 Absorption
    • 2.1.2 Distribution
    • 2.1.3 Metabolism
      • 2.1.3.1 MIST Guidelines
    • 2.1.4 Excretion
    • 2.1.5 Toxicology
  • 2.2 The Role of ADMET Testing in Biosimilarity
  • 2.3 Trial Design and Execution
    • 2.3.1 Phases of Drug Development
      • 2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties
      • 2.3.1.2 Phase I Trials: First-In-Human Studies
      • 2.3.1.3 Phase II Trials: Proof-Of-Concept
      • 2.3.1.4 Phase III Trials: Preparing for Approval Applications
      • 2.3.1.5 Post-Marketing Studies
    • 2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET
    • 2.3.3 Benefits of Outsourcing

3. ADMET Testing: World Market 2015-2027

  • 3.1 Pharma R&D Expenditures by Phase, 2014
    • 3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014
    • 3.1.2 Big Pharma Companies Are the Leading Clients for CROs
  • 3.2 The ADMET Testing Market 2015-2027
    • 3.2.1 What Will Drive Growth in ADMET Testing 2015-2027?
    • 3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2027

4. ADMET Testing: Revenue by Segment 2015-2027

  • 4.1 Which Market Sector Will Account for the Most Revenue from 2015-2027?
  • 4.2 Rising Demand for Predictive ADMET Testing Throughout the Decade
  • 4.3 In Vitro ADMET Testing Market
    • 4.3.1 In Vitro ADMET Testing: Drivers and Restraints
  • 4.4 In Vivo ADMET Testing Market
    • 4.4.1 In Vivo ADMET Testing: Drivers and Restraints
  • 4.5 In Silico ADMET Testing
    • 4.5.1 In Silico ADMET Testing: Drivers and Restraints

5. ADMET Testing: Leading Developed Markets 2015-2027

  • 5.1 Leading National Markets for ADMET Testing 2016
  • 5.2 ADMET Testing: Leading National Market Forecasts 2015-2027
  • 5.3 North America as a Destination for Drug Development
    • 5.3.1 The US: The Largest National Market for ADMET Testing 2015-2027
      • 5.3.1.1 Government Programs to Improve ADMET in the US
    • 5.3.2 The US: ADMET Testing Revenue Forecast 2015-2027
  • 5.4 The Outlook for ADMET Testing in the EU5 2015-2027
    • 5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
    • 5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2027
    • 5.4.3 Germany: Market Forecast 2015-2027
    • 5.4.4 The UK
      • 5.4.4.1 Overcoming Challenges in UK Clinical Trials
      • 5.4.4.2 UK ADMET Testing Market Forecast 2015-2027
    • 5.4.5 France: Market Forecast 2015-2027
    • 5.4.6 Italy: Market Forecast 2015-2027
    • 5.4.7 Spain: Market Forecast 2015-2027
  • 5.5 Japan Is Being Challenged by Neighbouring Emerging Markets
    • 5.5.1 Growth for ADMET Testing in Japan 2015-2027

6. ADMET: Leading Emerging Markets 2015-2027

  • 6.1 Leading Emerging Markets for ADMET Testing 2016
    • 6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets
    • 6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets
  • 6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2027
  • 6.3 ADMET in Asia Pacific: An Emerging Market Perspective
    • 6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025
      • 6.3.1.1 CRO Investments and Partnerships in China
      • 6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2027
    • 6.3.2 India as a Hub for Clinical Trials
      • 6.3.2.1 Indian ADMET Testing Market Forecast 2015-2027
    • 6.3.3 South Korea
      • 6.3.3.1 Promoting Local Drug Development in South Korea
      • 6.3.3.2 Growth in the South Korean ADMET Market 2015-2027
  • 6.4 Russia
    • 6.4.1 Changing Drug Development Demands 2010-2015
    • 6.4.2 Russian ADMET Market Forecast 2015-2027
  • 6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2027
    • 6.5.1 Brazilian ADMET Testing Market Forecast 2015-2027

7. Leading Companies in the ADMET Testing Industry

  • 7.1 Agilent Technologies, Inc.
    • 7.1.1 Agilent Technologies, Inc.: Historical Revenues 2014-2016
    • 7.1.2 Agilent Technologies, Inc. Acquires Cartagenia
  • 7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA
    • 7.2.1 Accelrys: Historical Revenues 2011-2013
  • 7.3 Cyprotex
    • 7.3.1 Evotec AG acquires Cyprotex
    • 7.3.2 Cyprotex Acquires CeeTox
    • 7.3.3 Cyprotex Historical Revenues, 2010-2014
  • 7.4 Bio-Rad Laboratories, Inc.
    • 7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2014-2016
  • 7.5 Quintiles
    • 7.5.1 Merger with IMS Health
    • 7.5.2 Expanding in Developed and Emerging Markets
  • 7.6 Increasing Asian Regional Reach
    • 7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist
  • 7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services
  • 7.8 WuXi PharmaTech
    • 7.8.1 Merger with New WuXi Life Science Limited and WuXi Merger Limited
    • 7.8.2 WuXi Acquires XenoBiotic Laboratories
    • 7.8.3 WuXi Enters the Clinical Trial Services Market
  • 7.9 Promega Corporation
  • 7.10 Merck KGaA's Acquisition of Sigma Aldrich

8. ADMET Testing Market: Industry Trends 2015-2027

  • 8.1 Strengths and Weaknesses of the ADMET Testing Market
  • 8.2 Opportunities and Threats in the ADMET Testing Market
  • 8.3 ADMET Testing Market: STEP Analysis 2015-2027
    • 8.3.1 Social Factors Affecting ADMET 2015-2027
    • 8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing
  • 8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models
  • 8.5 Economic Considerations for ADMET Testing 2015-2027
    • 8.5.1 Demand for Predictive ADMET Testing
  • 8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2027
    • 8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development
    • 8.6.2 Strategic Partnering for Long Term Revenue Growth
      • 8.6.2.1 Sharing Risk Between Pharma and CROs
    • 8.6.3 A Note on CRO Selection
      • 8.6.3.1 Small Pharmaceutical Companies and CROs
    • 8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

9. Conclusions from Our Study

  • 9.1 The World ADMET Testing Market in 2016
    • 9.1.1 A Market Dominated by the Developed Countries
  • 9.2 Strong Growth for the Overall Market 2015-2027
  • 9.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
    • 9.3.1 How Can CROs Specialise to Remain Competitive?

Appendices

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015 and 2016
  • Table 2.1 Pharmacokinetics: Description of ADME
  • Table 2.2 Drug Delivery Routes
  • Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
  • Table 2.4 Founding Members of the ICH
  • Table 3.1 Breakdown of R&D Expenditures by Phase, 2014
  • Table 3.2 CRO Services Revenue by Customer Type, 2014
  • Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2017, 2020, and 2027
  • Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2016
  • Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.3 ADMET Testing: Market Shares by Country, 2016, 2020 and 2027
  • Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.5 EU5 ADMET Testing Market by Country, 2016
  • Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.1 Leading Emerging Markets for ADMET Testing, 2016
  • Table 6.2 Population Statistics in BRIC Nations, 2016
  • Table 6.3 English Proficiency in Emerging Markets, 2014
  • Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 7.1 Selected Companies in the ADMET Testing Industry, 2016
  • Table 7.2 Selected Agilent Technologies MS Products, 2016
  • Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2014-2016
  • Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2015 and 2016
  • Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013
  • Table 7.6 Cyprotex ADME & PK Services, 2016
  • Table 7.7 Cyprotex In Vitro Toxicology Services, 2016
  • Table 7.8 Cyprotex In Silico Services, 2016
  • Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2014-2016
  • Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2014-2016
  • Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2014-2016
  • Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2015 and 2016
  • Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
  • Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2016
  • Table 8.2 ADMET Testing Market: Opportunities and Threats, 2016
  • Table 8.3 ADMET Testing Market: STEP Analysis, 2016
  • Table 9.1 ADMET Testing Market by Sector: Revenue ($bn) and CAGR (%), 2016, 2020 & 2027

List of Figures

  • Figure 2.1 Drug Design Process
  • Figure 2.2 ADMET Parameters
  • Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
  • Figure 3.2 CRO Services Revenue by Customer Type, 2014
  • Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2027
  • Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2017, 2020 and 2027
  • Figure 4.2 ADMET Testing Submarket Shares (%), 2017
  • Figure 4.3 ADMET Testing Submarket Shares (%), 2020
  • Figure 4.4 ADMET Testing Submarket Shares (%), 2027
  • Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2027
  • Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2027
  • Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2027
  • Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2027
  • Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2027
  • Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2027
  • Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2027
  • Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2016
  • Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2020
  • Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2027
  • Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2016
  • Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2016
  • Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014
  • Figure 6.3 Relative Competence in English in Emerging Markets, 2014
  • Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2027
  • Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
  • Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2014-2016
  • Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2016
  • Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013
  • Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2014-2016
  • Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2014-2016
  • Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR(%), 2014-2016
  • Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2015 and 2016
  • Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
  • Figure 9.1 ADMET Testing Market Revenue ($bn) by Sector, 2016, 2020 & 2027

Companies Listed

  • AbD Serotec (now part of Bio-Rad Laboratories)
  • ACEA Biosciences
  • Aegis Analytical Corp
  • Agilent Technologies
  • Albany Molecular Research
  • Apredica, LLC
  • AstraZeneca
  • Bayer
  • BD Biosciences
  • Beckman Coulter
  • Bio-Rad Laboratories
  • BIOVIA
  • Boehringer Ingelheim
  • Caliper Life Sciences
  • Cambridge Cell Networks
  • Catalent Pharma Solutions
  • Catalina Health (now part of InVentiv Health)
  • Celerion
  • Cellartis
  • Cellectis AB
  • Cellumen
  • Celsis International
  • Charles River Laboratories
  • ChemSW
  • Clinipace Worldwide
  • ClinStar (now part of PRA Health Sciences)
  • CMIC Holdings
  • Cromos Pharma
  • CROMSOURCE
  • Cyprotex
  • EF Education First
  • Entelos Holdings
  • EPS Holdings, Inc., formerly EPS Corporation
  • Frontage Laboratories
  • GCP ClinPlus
  • I3 Research (now part of InVentiv Health)
  • ICON plc
  • INC Research
  • InVentiv Health
  • Harlan Laboratories (now part of Huntingdon Life Sciences)
  • Hisun Pharmaceuticals
  • Hospital Italiano of Buenos Aires
  • Huntingdon Life Sciences
  • JCL Bioassay Corporation (now part of CMIC)
  • Kendle (now part of INC Research)
  • Kforce Clinical Research (now part of InVentiv Health)
  • Life Technologies Corporation
  • LSK
  • Malaysian Biotechnology Corporation
  • Merck & Co.
  • Merck KGaA
  • Mitsubishi Gas Chemical Company, Inc.
  • MultiCASE
  • New York Stock Exchange
  • Noray Bioinformatics
  • Novartis
  • Novotech
  • Oncobiologics
  • Optivia Biotechnology
  • Organovo Holdings, Inc.
  • Parexel
  • PerkinElmer
  • Pharmaron
  • PharmaNet Development Group (now part of InVentiv Health)
  • PRA Health Sciences
  • Prodia Clinical Laboratory
  • Promega Corporation
  • Proteomics
  • ProTrials Research
  • Quintiles
  • ReSearch Pharmaceutical Services (now part of PRA Health Sciences)
  • Rosa & Co
  • Samsung
  • Sekisui Medical Co.
  • ShangPharma
  • Sigma-Aldrich
  • Simulations Plus
  • Sugi Medical Co. (now part of CMIC)
  • Taconic Biosciences
  • Takara Bio Europe AB
  • Takara Bio Inc
  • Tecan Group
  • Thermo Fisher Scientific
  • Tigermed Consulting
  • VelQuest
  • Vialis
  • West Coast Clinical Trials
  • WuXi PharmaTech
  • Xceleron
  • XenoBiotic Laboratories
  • XenoTech (now part of Sekisui)
  • Yungjin Pharmaceutical
  • Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd

Organizations Mentioned in the Report

  • Agenzia Italiana del Farmaco
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Associação Brasileira de CROs
  • Association of Clinical Trial Organisations (ACTO) [Russia]
  • Chinese Ministry of Commerce
  • Council for Economic Defense [Brazil]
  • Department of Health and Human Services [US]
  • Environmental Protection Agency [US]
  • European Commission
  • European Medicines Agency (EMA)
  • Fish and Wildlife Service [US]
  • Food and Drug Administration (FDA) [US]
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
  • Helmholtz Association
  • Helmholtz Zentrum München (German Research Center for Environmental Health)
  • Korea Drug Development Fund
  • Korea Food and Drug Administration (KFDA)
  • Korea National Enterprise for Clinical Trials
  • L'Agence Nationale de Sécurité du Médicament (l'ANSM)
  • Les Entreprises du Medicament (LEEM)
  • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
  • Nagoya University
  • National Association for Biomedical Research [US]
  • National Cancer Institute (NCI) [US]
  • National Center for Advancing Translational Sciences [US]
  • National Centre for Computational Toxicology [US}
  • National Enterprise for Clinical Trials [South Korea]
  • National Human Genome Research Institute [US]
  • National Institute of Environmental Health Sciences [US]
  • National Institutes of Health (NIH) [US]
  • National Toxicology Program [US]
  • New England Antivivisection Society
  • Russian Ministry of Public Health
  • Seoul National University Hospital Clinical Trials Center
  • Shanghai Clinical Research Center
  • Vietnam Ministry of Health Administration of Science, Technology and Training (ASST)
  • World Health Organization (WHO)
Back to Top